Yttrium (90Y) tacatuzumab tetraxetan
From Wikipedia, the free encyclopedia
(Redirected from Tacatuzumab tetraxetan)
 |
|
|---|---|
| Monoclonal antibody | |
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | α-fetoprotein |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 500784-58-7  |
| ATC code | None |
| Chemical data | |
| Formula | C6470H9971N1712O2007S4290Y |
| Mol. mass | 145 kDa |
 (what is this?) (verify) |
|
Yttrium (90Y) tacatuzumab tetraxetan (trade name AFP-Cide) is a humanized monoclonal antibody intended for the treatment of cancer.[1] The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90,[2] a radioisotope which destroys the tumour cells.
[edit] References
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
